Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention

Inclusion Criteria:

- Have completed active primary treatment

- defined as surgery chemotherapy and/or radiation for the treatment of breast
cancer

- Does not include immunotherapy or other targeted therapies such as trastuzumab,
CDK 4/6 or mTOR inhibitors

- Have been receiving AIs for at least 6 months prior to enrollment

- Plan to continue AIs for an additional 3 months

- Postmenopausal for at least 12 months at enrollment

- Menopause will be defined as amenorrhea for 12 months regardless of cause

- Participants must be able to read and write in English

- Participants must have < 2% superficial vaginal cells on cytologic evaluation

Exclusion Criteria:

- Pre-existing hypertonic pelvic floor dysfunction identified in the medical record

- Unresolved or recurrent vaginismus identified in the medical record

- Aversion to touching one's own body, including genitals, or using vibration therapy on
the genitals

- Currently receiving estrogen therapy, including topical and/or systemic estrogens

- Have received estrogen therapy within 6 months of study enrollment, including topical
and/or systemic estrogens

- Any surgical procedure to the vagina or vulva, excluding office biopsies, within the
previous 12 months

- Receipt of pelvic or vaginal or vulvar radiation therapy within the 12 months prior to
enrollment or if the subject is anticipated to receive radiation targeted to any of
these 3 locations within 6 months following enrollment

- Any use of the VRP off study within the last 6 months